68Ga-PSMA-617 PET/CT was performed on Biograph 40 PET/CT scanner (Siemens, Germany), 68Ge/68Ga-generator was from ITG company (Germany), and PSMA-617 ligand was from ABX company (Germany). 68Ga-PSMA-617 was prepared according to a previously published method17 (link) with a radiochemical purity of > 95%. The 68Ga-PSMA-617 prepared was administered via elbow vein injection at a dose of 3–5 mCi. Whole-body PET scans were acquired approximately 60 min after tracer injection. No adverse or clinically detectable pharmacological effects were observed in any of the enrolled patients.
Biograph 40 pet ct scanner
Manufactured by Siemens
Sourced in Germany
The Biograph 40 PET/CT scanner is a medical imaging device that combines positron emission tomography (PET) and computed tomography (CT) technologies. The core function of the Biograph 40 is to acquire and integrate high-quality PET and CT images, providing healthcare professionals with comprehensive diagnostic information.
Automatically generated - may contain errors
Lab products found in correlation
9 protocols using biograph 40 pet ct scanner
1
Gallium-68 PSMA-617 PET/CT Imaging
2
Protocol for [18F]HX4 PET/CT Imaging of Tumors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
[18F]HX4 was produced as described in previous publications [9 (link), 16 (link)–18 (link)]. After intravenous administration of an average (±SD) dose of 378 ± 84 MBq [18F]HX4, PET/CT imaging was performed at 1.5, 3, and 4 h post-injection (p.i.) for 15, 15, and 20 min, respectively, for a single bed position centred around the primary tumour. After ten patients, an interim analysis showed highest contrast at the imaging time-point at 4 h p.i., and this was used from then onwards.
[18F]HX4 PET/CT scans were acquired before the start of external beam radiotherapy and during the radiation treatment; after an average (±SD) dose of 21 ± 2 Gy using a Biograph 40 PET/CT scanner (Siemens Healthcare, Erlangen, Germany). Scatter and attenuation corrections were applied, PET images were reconstructed using OSEM 2D (Ordered Subset Expectation Maximization, four iterations, eight subsets) and a Gaussian filter of 5 mm. Imaging was performed in radiotherapy position, with the patient positioned on a flat table top using an immobilization mask and a movable laser alignment system.
[18F]HX4 PET/CT scans were acquired before the start of external beam radiotherapy and during the radiation treatment; after an average (±SD) dose of 21 ± 2 Gy using a Biograph 40 PET/CT scanner (Siemens Healthcare, Erlangen, Germany). Scatter and attenuation corrections were applied, PET images were reconstructed using OSEM 2D (Ordered Subset Expectation Maximization, four iterations, eight subsets) and a Gaussian filter of 5 mm. Imaging was performed in radiotherapy position, with the patient positioned on a flat table top using an immobilization mask and a movable laser alignment system.
3
Detailed Imaging Protocols for GAAIN and Knight ADRC Cohorts
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The imaging protocols for the GAAIN dataset have been described previously (Klunk et al., 2015 ). The PiB PET from the GAAIN dataset includes PET images acquired within the 50–70 min post-injection window at a minimum. The GAAIN_SUB dataset had full dynamic multi-frame PET imaging data acquired between 0 and 70 min after injection of PiB. T1-weighted MRI was also available to provide anatomical information and facilitate PET quantification.
For the Knight ADRC cohort, dynamic PET imaging was conducted for 1 h with a Siemens/CTI EXACT HR+ scanner or a Biograph 40 PET/CT scanner (Siemens Medical Solutions, Erlangen, Germany) in three-dimensional mode after intravenous administration of approximately 12 mCi of PiB. Anatomic MRI was acquired with a T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence using a Siemens 1.5 T or 3 T scanner.
For the Knight ADRC cohort, dynamic PET imaging was conducted for 1 h with a Siemens/CTI EXACT HR+ scanner or a Biograph 40 PET/CT scanner (Siemens Medical Solutions, Erlangen, Germany) in three-dimensional mode after intravenous administration of approximately 12 mCi of PiB. Anatomic MRI was acquired with a T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) sequence using a Siemens 1.5 T or 3 T scanner.
4
Tau-PET Imaging for Alzheimer's Biomarkers
5
Multimodal Neuroimaging Acquisition Protocol
6
Amyloid PET Imaging Protocols for Lewy Body Dementia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Imaging was performed at baseline. Details of the MRI and PET acquisition and analysis have been published previously.23 (link)
25 In summary, PET-Aβ imaging data were available for 59 participants with LBD. For the NIMROD and MILOS cohort 550 MBq of [11C] PIB PET imaging was carried out using a GE Advance PET scanner (GE Healthcare) or a GE Discovery 690 PET/CT, with attenuation correction provided by a transmission scan or a low dose CT scan, with 550 MBq of PIB injected as a bolus and imaging performed for 30 min starting at 40 min post injection. Participants were considered PET-Aβ-positive using a cutpoint of 19 on the centiloid scale.28 (link)For the AMPLE cohort imaging was performed using a Siemens Biograph-40 PET-CT scanner. Participants were given a 370 MBq intravenous injection of 18F-florbetapir (Amyvid). PET imaging was carried out for 15 min, commencing 30−50 min after injection. Attenuation correction was performed using CT scan data. Amyloid PET images were visually rated as positive or negative based on the manufacturer’s criteria by a panel of five raters.23 (link)
25 In summary, PET-Aβ imaging data were available for 59 participants with LBD. For the NIMROD and MILOS cohort 550 MBq of [11C] PIB PET imaging was carried out using a GE Advance PET scanner (GE Healthcare) or a GE Discovery 690 PET/CT, with attenuation correction provided by a transmission scan or a low dose CT scan, with 550 MBq of PIB injected as a bolus and imaging performed for 30 min starting at 40 min post injection. Participants were considered PET-Aβ-positive using a cutpoint of 19 on the centiloid scale.28 (link)For the AMPLE cohort imaging was performed using a Siemens Biograph-40 PET-CT scanner. Participants were given a 370 MBq intravenous injection of 18F-florbetapir (Amyvid). PET imaging was carried out for 15 min, commencing 30−50 min after injection. Attenuation correction was performed using CT scan data. Amyloid PET images were visually rated as positive or negative based on the manufacturer’s criteria by a panel of five raters.23 (link)
7
Multimodal Brain Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Imaging was performed at baseline. Details of the MRI and PET acquisition and analysis have been published elsewhere [23] and will briefly be summarised here.
Brain MRI scans were acquired using a 3T MR scanner (Achieva scanner; Philips Medical Systems), with body coil transmission and eight channel head coil receiver. Images acquired included a 3D sagittal magnetisation-prepared rapid gradient echo (MPRAGE) sequence (repetition time 8.3ms, echo time 4.6ms, flip angle 8°, inversion delay 1250ms, imaging time 4.5mins, sagittal acquisition matrix 216x240, voxel size 1x1x1mm) and echo planar imaging spin echo (EPI-SE) diffusion tensor imaging (TR 6126ms, TE 70ms, 124x120 matrix ; 270x270 FOV; 59 slices with slice thickness 2.11mm). Diffusion weighting was in 64 directions with a b value of 1000s/mm 2 along with 6 images with b value of 0 s/mm 2 . Amyloid imaging was carried out using a Siemens Biograph-40 PET-CT scanner. Participants were given a 370MBq intravenous injection of 18 F-Florbetapir (Amyvid) followed by a 15 minute scan starting 30-50 minutes after injection to image amyloid distribution. Images were reconstructed using iterative reconstruction (4 iterations, 16 subsets), with a 168x168 matrix size, 2.04x2.04mm pixel size, 3mm slice thickness, and 3mm post-reconstruction Gaussian filter. Attenuation correction was performed utilising CT scan data.
Brain MRI scans were acquired using a 3T MR scanner (Achieva scanner; Philips Medical Systems), with body coil transmission and eight channel head coil receiver. Images acquired included a 3D sagittal magnetisation-prepared rapid gradient echo (MPRAGE) sequence (repetition time 8.3ms, echo time 4.6ms, flip angle 8°, inversion delay 1250ms, imaging time 4.5mins, sagittal acquisition matrix 216x240, voxel size 1x1x1mm) and echo planar imaging spin echo (EPI-SE) diffusion tensor imaging (TR 6126ms, TE 70ms, 124x120 matrix ; 270x270 FOV; 59 slices with slice thickness 2.11mm). Diffusion weighting was in 64 directions with a b value of 1000s/mm 2 along with 6 images with b value of 0 s/mm 2 . Amyloid imaging was carried out using a Siemens Biograph-40 PET-CT scanner. Participants were given a 370MBq intravenous injection of 18 F-Florbetapir (Amyvid) followed by a 15 minute scan starting 30-50 minutes after injection to image amyloid distribution. Images were reconstructed using iterative reconstruction (4 iterations, 16 subsets), with a 168x168 matrix size, 2.04x2.04mm pixel size, 3mm slice thickness, and 3mm post-reconstruction Gaussian filter. Attenuation correction was performed utilising CT scan data.
8
Amyloid PET Imaging Protocols for Lewy Body Dementia
9
Multimodal Brain Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Imaging was performed at baseline. Details of the MRI and PET acquisition and analysis have been published elsewhere [22 (link)] and will briefly be summarised here.
Brain MRI scans were acquired using a 3T MR scanner (Achieva scanner; Philips Medical Systems), with body coil transmission and eight channel head coil receiver. Images acquired included a 3D sagittal magnetisation-prepared rapid gradient echo (MPRAGE) sequence (repetition time 8.3 ms, echo time 4.6 ms, flip angle 8°, inversion delay 1250 ms, imaging time 4.5 mins, sagittal acquisition matrix 216 × 240, voxel size 1 × 1x1mm) and T2*-weighted sequence (TR 1487 ms, TE 16.11 ms, flip angle 18°, 50 slices with 3 mm thickness (0 mm gap), voxel size 0.898 × 1.12 mm).
Amyloid imaging was carried out using a Siemens Biograph-40 PET-CT scanner with data acquired in list mode. Participants were given a 370 MBq intravenous injection of 18F-florbetapir (Amyvid), followed immediately by a 5 min scan for perfusion images, with a subsequent 15 min scan starting 30–50 min after injection to image amyloid distribution. Images were reconstructed using iterative reconstruction (4 iterations, 16 subsets), with a 168 × 168 matrix size, 2.04 × 2.04 mm pixel size, 3 mm slice thickness, and 3 mm post-reconstruction Gaussian filter. Attenuation correction was performed utilising CT scan data.
Brain MRI scans were acquired using a 3T MR scanner (Achieva scanner; Philips Medical Systems), with body coil transmission and eight channel head coil receiver. Images acquired included a 3D sagittal magnetisation-prepared rapid gradient echo (MPRAGE) sequence (repetition time 8.3 ms, echo time 4.6 ms, flip angle 8°, inversion delay 1250 ms, imaging time 4.5 mins, sagittal acquisition matrix 216 × 240, voxel size 1 × 1x1mm) and T2*-weighted sequence (TR 1487 ms, TE 16.11 ms, flip angle 18°, 50 slices with 3 mm thickness (0 mm gap), voxel size 0.898 × 1.12 mm).
Amyloid imaging was carried out using a Siemens Biograph-40 PET-CT scanner with data acquired in list mode. Participants were given a 370 MBq intravenous injection of 18F-florbetapir (Amyvid), followed immediately by a 5 min scan for perfusion images, with a subsequent 15 min scan starting 30–50 min after injection to image amyloid distribution. Images were reconstructed using iterative reconstruction (4 iterations, 16 subsets), with a 168 × 168 matrix size, 2.04 × 2.04 mm pixel size, 3 mm slice thickness, and 3 mm post-reconstruction Gaussian filter. Attenuation correction was performed utilising CT scan data.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!